Revolution Medicines Reports Daraxonrasib Survival Benefit Across PDAC Subgroups
Exploratory Phase 3 RASolute 302 subgroup data showed median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy (HR 0.40) in previously treated metastatic PDAC, consistent with the primary analysis.
Revolution Medicines reported exploratory subgroup findings from Phase 3 RASolute 302. Daraxonrasib improved overall survival versus chemotherapy across RAS subgroups in previously treated metastatic PDAC, consistent with the primary analysis. Median overall survival was 13.2 vs 6.7 months (HR 0.40).